EGFR and non-small cell lung carcinoma: The discovery of EGFR-TKIs has dramatically improve the survival outcomes of advanced NSCLC patients with EGFR-TKIs sensitive mutations, and EGFR-TKIs consequently has been recommended as first-line therapy for advanced NSCLC with sensitizing EGFR mutations.